Play Video

Evidence-based gut health solutions

Products & Pipeline

Gastrointestinal ReProgramming (GaRP) Product

Introducing GaRP as a multicomponent, multicoated complementary medicine.
Anatara’s GaRP product has been designed to address primary underlying factors contributing to chronic gastrointestinal tract (GIT) disorders such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD).In particular, the mechanism of action is designed to restore and maintain the lining of the GIT as a barrier and to contribute to the homeostasis of the microbiome.
The causative factors of IBS and IBD are understood to be complex and multifactorial, and both these conditions share the features of inflammation of the GIT lining, increased intestinal permeability (leakage) and dysbiosis of the microbiome.

pathophysiological mechanisms of IBD and IBS

Successful GaRP proof of concept studies

In February and October 2019, Anatara reported positive in vitro proof of concept data and statistically significant efficacy data from its in vivo mouse studies for its Gastrointestinal ReProgramming (GaRP) product.
Through these studies, Anatara has been able to demonstrate that GaRP has been shown to:

GaRP has been shown to

Further information

Following successful proof of concept studies for the Company’s gastrointestinal complementary medicine in reducing inflammation and pro-inflammatory gut bacteria, recruitment for a human clinical study in IBS patients commenced in August 2021.

Why a Complementary
Medicine?

GI disorders affect a significant proportion of the population at some stage of their life, with IBS affecting more than 20% of the Australian population.
Our lead product is being positioned as an adjunct to existing therapies. Over the last 20 years the use of complementary medicine as adjuncts to prescription drugs has increased significantly.
Approximately 50% of IBS and 30-50% of IBD patients seek additional relief of their symptoms through the use of complementary and alternative medicines (CAMs) – this approach is generally precipitated by the high failure rates and severe side-effects of current prescription therapies. As the role of a dysfunctional gut microbiome and inflammation are central to the initiation and perpetuation of IBD and IBS, there is an urgent need for CAMs that can rectify these underlying conditions

Further information

We’re progressing innovative,
evidence-based health solutions
Want to stay up to date with our trials and latest news?
Sign up here

    All rights reserved © Anatara Lifesciences 2024